Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

59P - Real-world data of immunotherapy in patients over 65 years old with lung cancer


09 Dec 2020


e-Poster Display Session


Geriatric Oncology

Tumour Site

Non-Small Cell Lung Cancer


Beatriz Nuñez-Garcia


Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391


B. Nuñez-Garcia, Y. Garitaonaindía Díaz, M. Martinez-Cutillas, M. Blanco, R. Aguado

Author affiliations

  • Puerta de Hierro University Hospital, Madrid/ES

Abstract 59P


Immunotherapy (IO) has become one of the leading treatments for advanced lung cancer. The number of elderly patients treated in routine clinical practice contrasts with the low representation of these in clinical trials. The aim of the study is to establish clinical differences between patients older and younger than 65 years treated with IO.


We conducted a single centre retrospective review including 137 patients treated with IO in Puerta de Hierro University Hospital (Madrid) between 2014 and 2019. We collected information regarding epidemiology, treatments, response and survival patterns and we performed a comparative analysis between patients <65 and ≥ 65 years.


Clinical data, toxicities, treatments and survival are shown in the table. There were no differences in high grade toxicities (9.1% vs 10.4%) or treatment interruption (20.3% vs 17.6%, p=0.576). We didn´t find difference in OS (16.0 vs 17.0) between both groups.

Table: 59P

<65 (69) >65 (68) Long rank (p)
Sex M F 54.5% 45.6% 74.6% 25.4%
Age 58 72
ECOG 0-1 ≥2 93.2% 4.5% 97.0% 3.0%
Histology Adenocarcinoma Squamous Small cell Others 59.1% 27.3% 2.3% 11.4% 56.7% 25.4% 4.5% 13.4%
Toxicity type Asthenia Pneumonitis Thyroid disorders Skin Others 11.4% 14.8% 10.2% 9.1% 24.9% 13.4% 11.9% 11.9% 9.0% 19.5%
Grade 1-2 ≥3 23.8% 9.1% 28.3% 10.4% 0.99
Treatments (CI, 95%)
Median OS 16.0 (9.1-22.9) 17.0 (7.5-26.5) 0.825
1° line
Median PFS 3.0 (0-6.8) 7.0 (1.2-12.8) 0.164
Duration (median) 3.0 3.0
2° line
Median PFS 11.0 (9.6-12.4) 11.0 (5.1-16.9) 0.837
Duration (median) 9.5 4.0
3° line
Median PFS 2.0 (1.2-2.8) 2.0 (0.1-3.9) 0.338
Duration (median) 2.0 2.0


Our results show that IO has an adequate safety profile in patients ≥65 years and survival results are similar to young patients. Therefore, in our opinion, IO represents a valid and safe option for advanced lung cancer treatment in patients ≥65 years.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.